Plant Name: Mimosa pudica
Taxonomic Information:
Plant ID: NPO7191
Plant Latin Name: Mimosa pudica
Taxonomy Genus: Mimosa
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
76306
Plant-of-the-World-Online:
313242-2
Used in Medicines:
Country/Region:
South Africa; Guinea; Philippines; Indonesia; India; Malaysia; Vietnam; China; Laos; Thailand; NigeriaTraditional Medicine System:
Sowa-Rigpa; Indian Folk; TCM; Ayurveda; SiddhaGeographical Distribution:
Brazil; Madagascar; Bangladesh; Sudan; Guinea; Nepal; Costa Rica; Cambodia; Bahamas; Tanzania; Laos; Nigeria; Cameroon; Cote d'Ivoire; Ecuador; Benin; Ghana; Australia; Vanuatu; Cuba; El Salvador; Burkina Faso; Togo; Guatemala; Zimbabwe; China; Thailand; Dominican Republic; Belize; Sierra Leone; Liberia; Maldives; Uganda; Pakistan; Gambia; Philippines; Indonesia; New Caledonia; Vietnam; Gabon; Malawi; Haiti; Jamaica; Seychelles; Mexico; South Africa; India; Malaysia; Senegal; Congo; Colombia; Sri Lanka; Kenya; Taiwan; Nicaragua
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2C; ADRB3; ADRA2A; ADRA2B; DRD2; | |
| TDP1; APEX1; | |
| CA9; | |
| PTGS1; PTGS2; MAOA; | |
| NOX1; | |
| SLC6A2; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP1A2; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRB3 | Beta-3 adrenergic receptor | P13945 | CHEMBL246 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Transmembrane 1-electron transfer carriers | NOX1 | NADPH oxidase 1 | Q9Y5S8 | CHEMBL1287628 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 2.065E-12 | 1.499E-08 | ADRA2A, ADRA2B, ADRA2C, ADRB3, DRD2 |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 1.645E-11 | 7.163E-08 | ADRA2A, ADRA2B, ADRA2C, ADRB3 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 3.789E-10 | 1.179E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0008217; regulation of blood pressure | 8.999E-10 | 2.177E-06 | ADRA2B, ADRB3, DRD2, NOX1, PTGS1, PTGS2 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.515E-09 | 2.998E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.515E-09 | 2.998E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 2.117E-08 | 2.426E-05 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0031690; adrenergic receptor binding | 3.070E-07 | 1.966E-04 | ADRA2A, ADRA2C, ADRB3 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 5.629E-07 | 3.405E-04 | PTGS1, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0006950; response to stress | 8.107E-07 | 4.526E-04 | ADRB3, APEX1, CA9, CYP1A2, DRD2, LMNA, NOX1, PTGS1, PTGS2, SLC6A2, TDP1 |
| BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 1.360E-06 | 7.264E-04 | ADRA2A, ADRA2B, ADRA2C, ADRB3, DRD2, NOX1 |
| BP | GO:0009987; cellular process | GO:0045744; negative regulation of G-protein coupled receptor protein signaling pathway | 1.681E-06 | 8.512E-04 | ADRA2A, ADRB3, DRD2 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 2.126E-06 | 9.848E-04 | ADRB3, APEX1, CYP1A2, MAOA, NOX1, PTGS1, PTGS2 |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 2.235E-06 | 1.014E-03 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0051380; norepinephrine binding | 5.621E-06 | 2.186E-03 | ADRA2A, ADRB3 |
| BP | GO:0051179; localization | GO:0051926; negative regulation of calcium ion transport | 1.608E-05 | 5.304E-03 | ADRA2A, DRD2, PTGS2 |
| CC | GO:0016020; membrane | GO:0016020; membrane | 2.732E-05 | 8.149E-03 | ADRA2A, ADRA2B, ADRA2C, ADRB3, CA9, CYP1A2, DRD2, LMNA, MAOA, NOX1, PTGS1, PTGS2, SLC6A2, TDP1 |
| BP | GO:0008152; metabolic process | GO:0019371; cyclooxygenase pathway | 3.083E-05 | 8.952E-03 | PTGS1, PTGS2 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.318E-06 | 6.984E-05 | ADRB3, ADRA2C, DRD2, ADRA2B, ADRA2A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 5.958E-06 | 1.579E-04 | ADRB3, ADRA2C, ADRA2B, ADRA2A |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 9.238E-06 | 1.632E-04 | ADRB3, PTGS2, PTGS1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 7.406E-05 | 9.813E-04 | MAOA, PTGS2, PTGS1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.028E-04 | 4.270E-03 | MAOA, CYP1A2 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 6.050E-04 | 5.344E-03 | MAOA, DRD2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 9.673E-04 | 7.324E-03 | PTGS2, PTGS1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.196E-03 | 7.927E-03 | MAOA, CYP1A2 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.684E-03 | 9.918E-03 | CYP1A2, PTGS2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | ADRB3; PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C; ADRB3; DRD2; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; MAOA; PTGS1; PTGS2; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | ADRB3; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2; DRD2; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2; CA9; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; CA9; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | ADRB3; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | ADRB3; DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | SLC6A2; DRD2; MAOA; |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
| NA: NA | False perceptions | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; PTGS1; PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; DRD2; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; DRD2; MAOA; PTGS2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADRB3; DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; ADRA2C; DRD2; MAOA; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2; PTGS2; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; PTGS2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; |
| NA: NA | Miosis during ocular surgery | NA | PTGS1; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | ADRB3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; SLC6A2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2; NOX1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; ADRB3; SLC6A2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADRB3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; SLC6A2; MAOA; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | ADRB3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | ADRB3; SLC6A2; DRD2; MAOA; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ADRB3; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA2C; ADRB3; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; SLC6A2; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2; |
| NA: NA | Hyperaemia | NA | DRD2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C; ADRB3; DRD2; PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD2; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| NA: NA | Itching | NA | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD2; MAOA; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2A; ADRA2C; SLC6A2; DRD2; PTGS1; PTGS2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; PTGS1; PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| NA: NA | Vomiting | NA | DRD2; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C; SLC6A2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
